Related Experiment Video
Updated: Jun 28, 2025
09:08
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
1.9K
Inhibiting the cGAS-STING Pathway in Ulcerative Colitis with Programmable Micelles
Saji Uthaman1,2, Shadi Parvinroo2,3, Ansuja Pulickal Mathew1,2
1Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011, United States.
ACS Nano
|April 22, 2024
Summary
New nanomicelles effectively treat ulcerative colitis by targeting inflammation. These STING-inhibiting micelles (SIMs) reduce immune response and restore colon health, offering a promising therapy for inflammatory bowel disease.
Area of Science:
- Nanotechnology
- Immunology
- Gastroenterology
Background:
- Ulcerative colitis involves immune dysregulation causing intestinal inflammation.
- Current therapies for ulcerative colitis have limited effectiveness and side effects.
Purpose of the Study:
- To develop programmable nanomicelles for targeted ulcerative colitis treatment.
- To inhibit the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway.
Main Methods:
- Designed STING-inhibiting micelles (SIMs) using hyaluronic acid-stearic acid and a ROS-responsive linker.
- Utilized HA-CD44 binding for targeted accumulation at inflammation sites.
- Administered SIMs orally in murine models of colitis (preventive and therapeutic).
Main Results:
- SIMs selectively targeted inflamed colonic tissue via HA-CD44 interaction.
- Oral SIM delivery reduced STING expression and pro-inflammatory cytokines.
- SIM treatment ameliorated colitis severity, improved body weight, preserved colon length, and restored epithelium.
Conclusions:
- Programmable nanomicelles show potential for ulcerative colitis treatment.
- Targeting the cGAS-STING pathway with nanomicelles reduces intestinal inflammation.
- This approach offers a novel strategy for managing inflammatory bowel diseases.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
423
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
423
01:21Drugs for Treatment of Constipation-Predominant IBS
161
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
161
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
392
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
392
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
472
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
472
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
399
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
399